Biodol Therapeutics is pioneering the development of first-in-class compounds aimed at treating chronic pain, particularly neuropathic pain (NP). The company has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a crucial factor in the onset and persistence of chronic pain. Their research indicates that inhibiting FLT3 not only alleviates key symptoms of NP—such as allodynia, pain hypersensitivity, and spontaneous pain—but also enhances the effectiveness of opioids while mitigating the risks of opioid tolerance. This innovative approach is supported by a strong intellectual property portfolio, including patents that cover the use of FLT3 inhibitors in conjunction with opioids, positioning Biodol Therapeutics as a unique player in the pain management market.

The company is advancing a pipeline of small-molecule FLT3 inhibitors, known as BDT compounds, which have shown significant efficacy in preclinical models. These compounds act as Negative Allosteric Modulators, targeting the extracellular domain of FLT3 to inhibit ligand binding. Biodol's lead compounds have demonstrated the ability to completely reverse established neuropathic pain symptoms with a single administration, while also potentiating morphine's analgesic effects and preventing morphine-induced tolerance. This dual action not only addresses chronic pain more effectively but also offers a potential solution to the ongoing opioid crisis, making Biodol Therapeutics a promising candidate for investment and collaboration in the biopharmaceutical sector.

France

BIODOL Therapeutics is a biotech company developing first-in-class compounds for treating chronic pain. It is based on the discovery by Biodol's scientists of the target FLT3, which is a master hub protein in the initiation and maintenance of neuropathic pain (Nature Communications 2018). Morevover, Biodol discovered that its FLT3 breakthrough platform will also help fighting the "Opioid Crisis"​ (patented but yet unpublished). Biodol has a series of FLT3 selective small-molecule extracellular antagonists. The Biodol's FLT3 technological Platform is worldwide protected by 5 patents.

BIODOL THERAPEUTICS

Company Details